Patents by Inventor Marco Seandel

Marco Seandel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis
    Patent number: 11913021
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: February 27, 2024
    Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin Rafii, Fan Zhang, Marco Seandel
  • METHODS AND COMPOSITIONS FOR PROMOTING SURVIVAL AND PROLIFERATION OF ENDOTHELIAL CELLS AND STIMULATING ANGIOGENSIS
    Publication number: 20210155899
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 27, 2021
    Applicants: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin RAFII, Fan ZHANG, Marco SEANDEL
  • Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis
    Patent number: 10865379
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 15, 2020
    Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin Rafii, Fan Zhang, Marco Seandel
  • METHODS AND COMPOSITIONS FOR PROMOTING SURVIVAL AND PROLIFERATION OF ENDOTHELIAL CELLS AND STIMULATING ANGIOGENSIS
    Publication number: 20180258386
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Application
    Filed: February 27, 2018
    Publication date: September 13, 2018
    Applicants: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin RAFII, Fan ZHANG, Marco SEANDEL
  • Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis
    Patent number: 9944897
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: April 17, 2018
    Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin Rafii, Fan Zhang, Marco Seandel
  • METHODS AND COMPOSITIONS FOR PROMOTING SURVIVAL AND PROLIFERATION OF ENDOTHELIAL CELLS AND STIMULATING ANGIOGENESIS
    Publication number: 20140045260
    Abstract: The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
    Type: Application
    Filed: May 20, 2013
    Publication date: February 13, 2014
    Applicant: Cornell Research Foundation, Inc.
    Inventors: Shahin RAFII, Fan ZHANG, Marco SEANDEL
  • Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
    Patent number: 8465732
    Abstract: The present invention relates to adenovirus E4ORF 1 gene and to endothelial cells engineered to express the E40RF 1 gene. The present invention also relates to uses of the E40RF 1 gene, and cells expressing the E40RF1 gene, and to compositions comprising the E4ORF 1 gene, or comprising cells expressing the E4ORF 1 gene.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: June 18, 2013
    Assignees: Cornell Research Foundation, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Shahin Rafii, Fan Zhang, Marco Seandel
  • GPR125 AS A MARKER FOR STEM AND PROGENITOR CELLS AND METHODS USE THEREOF
    Publication number: 20100330043
    Abstract: The present invention relates to GPR1 25 as a marker of stem and progenitor cells, including multipotent adult spermatogonial-derived stem cells (MASCs), spermatogonial stem and progenitor cells, skin stem or progenitor cells, intestinal stem or progenitor cells, neural stem or progenitor cells, and cancer stem cells. The invention provides, inter alia, methods for enriching or isolating GPR125-positive stem or progenitor cells, methods for detecting GPR125-positive stem or progenitor cells, methods for culturing GPR125-positive stem or progenitor cells, purified GPR125-positive stem or progenitor cells, therapeutic compositions containing purified GPR125-positive stem or progenitor cells, methods for targeting therapeutic agents to GPR125-positive stem and progenitor cells, and methods of treatment comprising administering GPR125-positive stem and progenitor cells, or differentiated cells derived therefrom, to subjects in need thereof.
    Type: Application
    Filed: October 23, 2007
    Publication date: December 30, 2010
    Applicants: CORNELL RESEARCH FOUNDATION, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Shahin Rafii, Sergey V. Shmelkov, Marco Seandel, Sai H. Chavala
  • METHODS AND COMPOSITIONS FOR PROMOTING SURVIVAL & PROLIFERATION OF ENDOTHELIAL CELLS & STIMULATING ANGIOGENESIS
    Publication number: 20100093081
    Abstract: The present invention relates to adenovirus E4ORF 1 gene and to endothelial cells engineered to express the E40RF 1 gene. The present invention also relates to uses of the E40RF 1 gene, and cells expressing the E40RF1 gene, and to compositions comprising the E4ORF 1 gene, or comprising cells expressing the E4ORF 1 gene.
    Type: Application
    Filed: January 18, 2008
    Publication date: April 15, 2010
    Applicants: CORNELL RESEARCH FOUNDATION, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Shahin Rafil, Fan Zhang, Marco Seandel
  • Monoclonal antibodies that recognize antigens associated with tumor metastasis
    Patent number: 6498014
    Abstract: This invention provides tumor metastasis-inhibiting monoclonal antibodies, mAb 41-2, mAb 50-6 and mAb 1A-5. The antigen recognized by mAb 50-6 and mAb 1A-5 has been identified as the PETA-3 antigen. The antigen recognized by mAb 41-2 has been identified as a novel tumor metastasis-associated antigen. Compositions and methods are provided that are useful for treating and diagnosing metastatic tumors.
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: December 24, 2002
    Assignee: The Research Foundation of State University of NY
    Inventors: Jacqueline E. Testa, James P. Quigley, Marco Seandel
  • Monoclonal antibodies that recognize antigens associated with tumor metastasis
    Patent number: 6245898
    Abstract: This invention provides tumor metastasis-inhibiting monoclonal antibodies, mAb 41-2, mAb 50-6 and mAb 1A-5. The antigen recognized by mAb 50-6 and mAb 1A-5 has been identified as the PETA-3 antigen. The antigen recognized by mAb 41-2 has been identified as a novel tumor metastasis-associated antigen. Compositions and methods are provided that are useful for treating and diagnosing metastatic tumors.
    Type: Grant
    Filed: June 15, 1999
    Date of Patent: June 12, 2001
    Assignee: The Research Foundation of State University of New York
    Inventors: Jacqueline E. Testa, James P. Quigley, Marco Seandel